litlas
Log inCreate account

David L. Porter

Active 1987–2026

Also published as
David L Porter
101
Papers
33,091
Citations
67
h-index
96
i10-index

Citations

Citations per year for David L. Porter1990: 3 citations1991: 4 citations1993: 2 citations1994: 1 citations1995: 1 citations1997: 1 citations2000: 4 citations2001: 6 citations2002: 8 citations2003: 12 citations2004: 9 citations2005: 13 citations2006: 13 citations2007: 14 citations2008: 5 citations2009: 8 citations2010: 9 citations2011: 37 citations2012: 102 citations2013: 263 citations2014: 227 citations2015: 439 citations2016: 505 citations2017: 619 citations2018: 788 citations2019: 1,795 citations2020: 2,228 citations2021: 1,882 citations2022: 1,601 citations2023: 1,292 citations2024: 2,021 citations2025: 1,154 citations2026: 35 citations1992: no citations, so this year is not shown1996: no citations, so this year is not shown1998–1999: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,534 citing papers, 33.8% of this breakdownChina: 1,713 citing papers, 12.8% of this breakdownGermany: 952 citing papers, 7.1% of this breakdownUnited Kingdom: 614 citing papers, 4.6% of this breakdownItaly: 524 citing papers, 3.9% of this breakdownFrance: 481 citing papers, 3.6% of this breakdownSpain: 395 citing papers, 3% of this breakdownCanada: 367 citing papers, 2.7% of this breakdownAustralia: 326 citing papers, 2.4% of this breakdownSwitzerland: 326 citing papers, 2.4% of this breakdownNetherlands: 287 citing papers, 2.2% of this breakdownJapan: 280 citing papers, 2.1% of this breakdown
0%33.8%Other 19.4%

Institutions

Fields

  • Medicine81.9%
  • Biochemistry, Genetics and Molecular Biology8.5%
  • Immunology and Microbiology7.3%
  • Engineering1.1%
  • Materials Science0.3%
  • Neuroscience0.3%
  • Other0.6%

Topics

  • CAR-T cell therapy research24.3%
  • Immune Cell Function and Interaction7.5%
  • Virus-based gene therapy research6.5%
  • Immunotherapy and Immune Responses5.1%
  • Nanowire Synthesis and Applications4.5%
  • Cancer Immunotherapy and Biomarkers3.6%
  • Other48.5%

Coauthors

All papers

Open in search
  1. Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

    Authors: Shannon L. Maude, Noelle V. Frey, Pamela A. Shaw, Richard Aplenc, David M. Barrett, Nancy Bunin, Anne Chew, Vanessa Gonzalez, Zhaohui Zheng, Simon F. Lacey, Yolanda D. Mahnke, J. Joseph Melenhorst, Susan R. Rheingold, Angela Shen, David T. Teachey, Bruce L. Levine, Carl H. June, David L. Porter, Stephan A. Grupp - New England Journal of Medicine 2014 cited by 5,408

  2. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

    Authors: Joseph A. Fraietta, Simon F. Lacey, Elena J. Orlando, Iulian Pruteanu-Malinici, Mercy Gohil, Stefan Lundh, Alina C. Boesteanu, Yan Wang, Roddy S. O’Connor, Wei‐Ting Hwang, Edward Pequignot, David E Ambrose, Changfeng Zhang, Nicholas S. Wilcox, Felipe Bedoya, Corin L. Dorfmeier, Chen Fang, Lifeng Tian, Harit Parakandi, Minnal Gupta, Regina M. Young, F. Brad Johnson, Irina Kulikovskaya, Li Liu, Jun Xu, Sadik H. Kassim, Megan M. Davis, Bruce L. Levine, Noelle V. Frey, Donald L. Siegel, Alexander C. Huang, E. John Wherry, Hans Bitter, Jennifer L. Brogdon, David L. Porter, Carl H. June, J. Joseph Melenhorst - Nature Medicine 2018 cited by 1,770

  3. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells

    Authors: J. Joseph Melenhorst, Gregory M. Chen, Meng Wang, David L. Porter, Changya Chen, McKensie Collins, Peng Gao, Shovik Bandyopadhyay, Hongxing Sun, Ziran Zhao, Stefan Lundh, Iulian Pruteanu-Malinici, Christopher L. Nobles, Sayantan Maji, Noelle V. Frey, Saar Gill, Alison W. Loren, Lifeng Tian, Irina Kulikovskaya, Minnal Gupta, David E Ambrose, Megan M. Davis, Joseph A. Fraietta, Jennifer L. Brogdon, Regina M. Young, Anne Chew, Bruce L. Levine, Donald L. Siegel, Cécile Alanio, E. John Wherry, Frederic D. Bushman, Simon F. Lacey, Kai Tan, Carl H. June - Nature 2022 cited by 947

  4. Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

    Authors: David L. Porter, Bruce L. Levine, Michael Kalos, Adam Bagg, Carl H. June - New England Journal of Medicine 2011 cited by 3,541

  5. Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

    Authors: Stephan A. Grupp, Michael Kalos, David M. Barrett, Richard Aplenc, David L. Porter, Susan R. Rheingold, David T. Teachey, Anne Chew, Bernd Hauck, J. Fraser Wright, Michael C. Milone, Bruce L. Levine, Carl H. June - New England Journal of Medicine 2013 cited by 3,491

  6. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

    Authors: Stephen J. Schuster, Jakub Svoboda, Elise A. Chong, Sunita D. Nasta, Anthony R. Mato, Özlem Anak, Jennifer L. Brogdon, Iulian Pruteanu-Malinici, Vijay Bhoj, Daniel J. Landsburg, Mariusz A. Wasik, Bruce L. Levine, Simon F. Lacey, J. Joseph Melenhorst, David L. Porter, Carl H. June - New England Journal of Medicine 2017 cited by 1,854

  7. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy

    Authors: Guido Ghilardi, Joseph A. Fraietta, James N. Gerson, Vivianna M. Van Deerlin, Jennifer J.D. Morrissette, Gabriel C. Caponetti, Luca Paruzzo, Jaryse Harris, Elise A. Chong, Sandra P. Susanibar-Adaniya, Jakub Svoboda, Sunita D. Nasta, Ositadimma Ugwuanyi, Daniel J. Landsburg, Eugenio Fardella, Adam Waxman, Emeline R. Chong, Vrutti Patel, Raymone Pajarillo, Irina Kulikovskaya, David Lieberman, Adam D. Cohen, Bruce L. Levine, Edward A. Stadtmauer, Noelle V. Frey, Dan T. Vogl, Elizabeth O. Hexner, Stefan K. Barta, David L. Porter, Alfred L. Garfall, Stephen J. Schuster, Carl H. June, Marco Ruella - Nature Medicine 2024 cited by 256

  8. T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

    Authors: Michael Kalos, Bruce L. Levine, David L. Porter, Sharyn I. Katz, Stephan A. Grupp, Adam Bagg, Carl H. June - Science Translational Medicine 2011 cited by 2,403

  9. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy

    Authors: Bruce L. Levine, Marcelo C. Pasquini, John E. Connolly, David L. Porter, Michael P. Gustafson, Jaap Jan Boelens, Edwin M. Horwitz, Stephan A. Grupp, Marcela V. Maus, Frederick L. Locke, Fabio Ciceri, Annalisa Ruggeri, John A. Snowden, Helen E. Heslop, Crystal L. Mackall, Carl H. June, Anna M. Sureda, Miguel‐Angel Perales - Nature Medicine 2024 cited by 196

  10. Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia

    Authors: David T. Teachey, Simon F. Lacey, Pamela A. Shaw, J. Joseph Melenhorst, Shannon L. Maude, Noelle V. Frey, Edward Pequignot, Vanessa Gonzalez, Fang Chen, Jeffrey Finklestein, David M. Barrett, Scott L. Weiss, Julie C. Fitzgerald, Robert A. Berg, Richard Aplenc, Colleen Callahan, Susan R. Rheingold, Zhaohui Zheng, Stefan Rose‐John, Jason C. White, Farzana Nazimuddin, Gerald Wertheim, Bruce L. Levine, Carl H. June, David L. Porter, Stephan A. Grupp - Cancer Discovery 2016 cited by 1,084

  11. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

    Authors: Melody Smith, Anqi Dai, Guido Ghilardi, Kimberly V. Amelsberg, Sean M. Devlin, Raymone Pajarillo, John Slingerland, Silvia Beghi, Pamela S. Herrera, Paul A. Giardina, Annelie Clurman, Emmanuel Agyemang Dwomoh, Gabriel K. Armijo, Antonio L. C. Gomes, Eric R. Littmann, Jonas Schlüter, Emily Fontana, Ying Taur, Jae H. Park, Maria Lia Palomba, Elizabeth Halton, Josel D. Ruiz, Tania Jain, Martina Pennisi, Aishat Olaide Afuye, Miguel‐Angel Perales, Craig W. Freyer, Alfred L. Garfall, Shannon Gier, Sunita D. Nasta, Daniel J. Landsburg, James N. Gerson, Jakub Svoboda, Justin R. Cross, Elise A. Chong, Sergio Giralt, Saar Gill, Isabelle Rivière, David L. Porter, Stephen J. Schuster, Michel Sadelain, Noelle V. Frey, Renier J. Brentjens, Carl H. June, Eric G. Pamer, Jonathan U. Peled, Andrea Facciabene, Marcel R.M. van den Brink, Marco Ruella - Nature Medicine 2022 cited by 309

  12. Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells

    Authors: Sangya Agarwal, M. Ángela Aznar, Andrew J. Rech, Charly R. Good, Shunichiro Kuramitsu, Tong Da, Mercy Gohil, Linhui Chen, Seok-Jae Albert Hong, Pranali Ravikumar, Austin K. Rennels, January Salas-McKee, Weimin Kong, Marco Ruella, Megan M. Davis, Gabriela Plesa, Joseph A. Fraietta, David L. Porter, Regina M. Young, Carl H. June - Immunity 2023 cited by 166

  13. Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy

    Authors: Noelle V. Frey, David L. Porter - Biology of Blood and Marrow Transplantation 2018 cited by 386

  14. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies

    Authors: Marco Ruella, David M. Barrett, Saad S. Kenderian, Olga Shestova, Ted J. Hofmann, Jessica Perazzelli, Michael Klichinsky, Vania Aikawa, Farzana Nazimuddin, Miroslaw Kozlowski, John Scholler, Simon F. Lacey, J. Joseph Melenhorst, Jennifer J.D. Morrissette, David A. Christian, Christopher A. Hunter, Michael Kalos, David L. Porter, Carl H. June, Stephan A. Grupp, Saar Gill - Journal of Clinical Investigation 2016 cited by 555

  15. Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia

    Authors: Julie C. Fitzgerald, Scott L. Weiss, Shannon L. Maude, David M. Barrett, Simon F. Lacey, J. Joseph Melenhorst, Pamela A. Shaw, Robert A. Berg, Carl H. June, David L. Porter, Noelle V. Frey, Stephan A. Grupp, David T. Teachey - Critical Care Medicine 2016 cited by 455

  16. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies

    Authors: Craig W. Freyer, David L. Porter - Journal of Allergy and Clinical Immunology 2020 cited by 206

  17. Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy

    Authors: Vijay Bhoj, Dimitrios C. Arhontoulis, Gerald Wertheim, James Capobianchi, Colleen Callahan, Christoph T. Ellebrecht, Amrom E. Obstfeld, Simon F. Lacey, J. Joseph Melenhorst, Farzana Nazimuddin, Wei‐Ting Hwang, Shannon L. Maude, Mariusz A. Wasik, Adam Bagg, Stephen J. Schuster, Michael D. Feldman, David L. Porter, Stephen Grupp, Carl H. June, Michael C. Milone - Blood 2016 cited by 271

  18. Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia

    Authors: Noelle V. Frey, Pamela A. Shaw, Elizabeth O. Hexner, Edward Pequignot, Saar Gill, Selina M. Luger, James K. Mangan, Alison W. Loren, Alexander E. Perl, Shannon L. Maude, Stephan A. Grupp, Nirav N. Shah, Joan Gilmore, Simon F. Lacey, Jos Melenhorst, Bruce L. Levine, Carl H. June, David L. Porter - Journal of Clinical Oncology 2019 cited by 269

  19. Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy

    Authors: Jaco A. C. van Bruggen, Anne W. J. Martens, Joseph A. Fraietta, Tom Hofland, Sanne H. Tonino, Eric Eldering, Mark‐David Levin, Peter J. Siska, Sanne Endstra, Jeffrey C. Rathmell, Carl H. June, David L. Porter, J. Joseph Melenhorst, Arnon P. Kater, Gerritje J. W. van der Windt - Blood 2019 cited by 186

  20. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

    Authors: Shannon L. Maude, David T. Teachey, David L. Porter, Stephan A. Grupp - Blood 2015 cited by 720

  21. Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas

    Authors: Guido Ghilardi, Elise A. Chong, Jakub Svoboda, Philipp Wohlfarth, Sunita D. Nasta, Staci Williamson, J.D. Landsburg, James N. Gerson, Stefan K. Barta, Raymone Pajarillo, Jessie Myers, A.I. Chen, Levanto Schachter, Rebecca Yelton, Hatcher J. Ballard, Alexandria Hodges Dwinal, Shannon Gier, Danielle Victoriano, Erin L. Weber, Ellen Napier, Alfred L. Garfall, David L. Porter, Ulrich Jäger, Richard T. Maziarz, Marco Ruella, Stephen J. Schuster - Annals of Oncology 2022 cited by 97

  22. Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia

    Authors: Karen Thudium Mueller, Shannon L. Maude, David L. Porter, Noelle V. Frey, Patricia A. Wood, Xia Han, Edward Waldron, Abhijit Chakraborty, Rakesh Awasthi, Bruce L. Levine, J. Joseph Melenhorst, Stephan A. Grupp, Carl H. June, Simon F. Lacey - Blood 2017 cited by 359

  23. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells

    Authors: Saar Gill, Sarah K. Tasian, Marco Ruella, Olga Shestova, Yong Li, David L. Porter, Martin Carroll, Gwenn Danet-Desnoyers, John Scholler, Stephan A. Grupp, Carl H. June, Michael Kalos - Blood 2014 cited by 491

  24. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance

    Authors: Michael Boyiadzis, Madhav V. Dhodapkar, Renier J. Brentjens, James N. Kochenderfer, Sattva S. Neelapu, Marcela V. Maus, David L. Porter, David G. Maloney, Stephan A. Grupp, Crystal L. Mackall, Carl H. June, Michael Bishop - Journal for ImmunoTherapy of Cancer 2018 cited by 247